Previously, we developed a vaccination regimen that involves priming with 28 recombinant vaccinia virus LC16 m8∆(rm8∆) strain followed by boosting with a 29
synonymously mutated in vitro using a mutagenesis kit (Stratagene). The env 131 fragment was then digested with Sac1 and ligated into the pVR1 vector [12] , which 132 had been digested with Sac1 and Sma1. BHK cells, which had been infected with 133 canarypox virus, were then co-transfected with the resultant plasmid and LC16m8∆ 134 genomic DNA to generate VV LC16m8∆-p7.5-JRCSFenv. HA -recombinants were 135 selected using erythrocytes isolated from white leghorn chickens (Sankyo Labo 136
Service Corporation, Inc.) [13, 14] . Expression of HIV-1 Env protein was examined 137
by Western blotting and plaque immunostaining. 138 139
Western Blotting 140
Vaccinia-infected-RK13 cells were lyzed and the proteins separated in 10% SDS-141 PAGE gels. Immunoblot analysis was performed with human antiserum from a HIV-142 1-infected patient or monoclonal mouse anti-β actin antibody, followed by alkaline 143 phosphatase-conjugated anti-human or mouse IgG (Promega). Proteins were 144 visualized using NBT/BCIP (Sigma). 145 146
Plaque immunostaining 147
RK13 cells were cultured in 6-well plates and infected with recombinant VV (at 148 approximately 100 plaque forming unit (pfu)/well). The cells were incubated with the 149 virus for 72 h at 33°C, fixed with 2% paraformaldehyde solution, and permeabilized 150 by incubating with 0.5% Nonidet P-40 for 1 min. The fixed cells were blocked with7 5% skimmed milk (in PBS) for 30 min at room temperature and incubated with the 152 primary antibody (HIV-1 infected human serum; diluted 1000-fold) for 1 h at room 153 temperature, followed by the secondary antibody (alkaline phosphatase-conjugated 154 anti-human IgG (Promega); diluted 2500-fold). The plaques were then stained with 155 NBT/BCIP. 156 157
Propagation potential of rm8∆ 158
To evaluate the propagation potential of LC16m8∆and its recombinants, RK13, 293T 159 and L929 cells (3 × 10 5 ) were infected with the viruses at a multiplicity of infection of 160 3 and then incubated for 24 h at 33°C. Progeny viruses were harvested and titrated on 161 a monolayer of RK13 cells in a plaque assay. 162 163
Immunization of mice 164
Seven-week-old female C57BL/6J mice (CLEA Japan) were administered with 165
LC16m8∆'s recombinants (each at 1 × 10 7 PFU by skin scarification). Eight weeks 166 later, the mice were boosted with rSeV expressing JRCSFenv (4 × 10 7 cell-infectious 167 unit (CIU)) via intranasal administration (i.n.). Mice were sacrificed at 2 or 8 weeks 168 after the final immunization, and serum and spleen samples were collected. 169 170
Intracellular cytokine staining (ICS) of splenocytes 171
Env-specific cellular immune responses were measured using an ICS assay as 172 described previously [2] . The percentage of IFN-γ + CD107a + T cells within the 173 CD4-or CD8-gated lymphocyte populations were determined using a FACSCanto 174 flow cytometer (BD biosciences) and the data were analyzed using FlowJo software 175 (Tree Star).
177

Evaluation of neutralizing activity 178
The HIV-1 neutralizing activity of the mouse sera was measured in a TZM-bl cell-179 based assay as previously described [2, 15, 16] . 180 181
Measurement of anti-Env antibody levels by ELISA 182
The titer and avidity of the anti-HIV-1 Env IgG antibodies in the mouse sera were 183 determined by ELISA as described previously [2] . 184
Safety of m8∆s 185
To evaluate the safety of the LC16m8∆ and m8Δ recombinants, 10 μl of a serially 186 diluted solution that contains 10 3 -10 7 pfu of rm8Δs was injected intracerebrally (i.c.) 187 into 10 to 17 of 2-3-day-old suckling Crlj:CD1 (ICR) mice (Charles River ). Survival 188 was then monitored daily for 2 weeks and the 50% lethal dose (LD50) was calculated 189
[17]. 190
Statistical analysis 191
Statistical analysis was performed using Student's t-test (Microsoft Excel version 192 11.6.6) . P values of <0.05, <0.01, and <0.001 were considered significant. The 193 survival of virus-injected suckling mice was evaluated using the log-rank test (R 194 CSFenv under the control of the p7.5 promoter (which is a moderate driver of foreign 209 gene expression) (Fig.1A) . We first compared expression of the Env protein in 210 various cells infected with m8∆-p7.5-JRCSFenv or m8∆-pSFJ-JRCSFenv by Western 211 blotting (Fig. 1B) . Regardless of the cell type, m8∆-p7.5-JRCSFenv produced several-212 fold less gp120/160 than m8∆-pSFJ-JRCSFenv. In addition, the bands corresponding 213 to gp120/160 expressed by cells infected with m8∆-pSFJ-JRCSFenv were much 214 broader than those expressed by cells infected with m8∆-p7.5-JRCSFenv. Meanwhile, 215 titration of the progeny virus after one-step growth revealed that the growth potential 216 of rVVs in mouse L929 cells are 10 times lower than that in human 293T cells and 217 rabbit RK13 cells (Fig 1C) , Nevertheless, m8∆-p7.5-JRCSFenv showed growth 218 potential similar to that of the parental m8∆, and significantly higher (6 to 50 fold) 219 than that of m8∆-pSFJ-JRCSFenv (Fig. 1C ). This indicates that overexpression of the 220 foreign gene suppresses viral propagation. 221 222
Immunogenicity of m8∆-p7.5-JRCSFenv and m8∆-pSFJ-JRCSFenv. 223 224
We next compared the immunogenicity of m8∆-p7.5-JRCSFenv and m8∆-pSFJ-225
JRCSFenv by using them to prime mice, which were then boosted with SeV-226 JRCSFenv according to the schedule outlined in Fig.2A boost; however, the difference between the groups was maintained (p=0.016). We 238 next measured the levels of Env-specific Abs (Fig. 3A) and anti-HIV-1-neutralizing 239 Abs (Fig. 3B ) in mice sera. The levels of anti-HIV-1 Env-specific IgG were 6-7-fold 240 higher in mice immunized with m8∆-pSFJ-JRCSFenv than in mice immunized with 241 m8∆-p7.5-JRCSFenv; this was in sharp contrast to the observed cellular responses 242 (Fig. 2) . The difference of humoral immunity had already been detected 6 weeks after 243 rm8∆ prime (supplementary data). The uneven of sample numbers between two 244 groups did not introduce bias into the data, since we obtained the same results when 245 two groups have the same number of animals (data not shown). Sera from both groups 246 of mice showed neutralizing activity against a tier 1 pseudotyped HIV-1 strain, SF162, 247 but only after rSeV boost, and no neutralization activity against tier 2 HIV-1s had 248 been detected. At both 2 and 8 weeks post-SeV-JRCSFenv boost, the neutralizing 249 competency of sera from mice immunized with m8∆-pSFJ-JRCSFenv was marginally 250 stronger than that of mice immunized with m8∆-p7.5-JRCSFenv; however, the 251 11 difference was not significant (Fig. 3B) . We also measured the avidity of the anti-Env 252 Abs in both groups: no significant difference was observed (Fig. 3C) . Since the m8∆-253 pSFJ-JRCSFenv prime/SeV-JRCSFenv boost elicited greater HIV-1 Env-specific 254 antibody responses, we next asked whether this antibody titer is maintained over the 255 long-term. We followed a subgroup of mice treated with this vaccination regimen for 256 28 weeks after the Sendai virus boost and found that the anti-HIV-1 Env antibody titer 257 was maintained throughout the observation period (Fig. 3D) . 258
Safety evaluation of the rm8Δin suckling mice 259 260
To evaluate the safety of rm8Δ, we i.c.-injected suckling mice with m8Δ, 261 m8∆VNC110, m8Δ-pSFJ-JRCSFenv, or m8Δ-p7.5-JRCSFenv. At 2 weeks post-262 injection, more of the mice in the m8ΔVNC110-and m8Δ-pSFJ-JRCSFenv-injected 263 (at 10 4 and 10 5 pfu) groups survived compared with those in the m8Δ-p7.
5-264
JRCSFenv-injected group (Fig. 4B, C, and D) . LC16m8Δwhich should be safe for 265 human use, showed the highest mortality (Fig 4A) . The median lethal doses (LD50) 266 for each strain were as follows: LC16m8Δ  3 PFU m8Δ-p7.5-JRCSFenv, 5.5 × 267  3 PFU; m8Δ-pSFJ-JRCSFenv, 1.4 × 10 5 PFU; and m8ΔVNC110, 5.75 × 10 5 PFU 268 (Fig. 4E) . These results suggest that both m8Δ-p7.5-JRCSFenv and m8Δ-pSFJ-269
JRCSFenv may be safer for use in humans. . It also indicated that gp41 but not gp120 is a 294 more potent inducer of cellular immunity when liberated from gp160 than it is when 295 buried in gp160. The amount of gp41 in m8∆-p7.5-JRCSFenv-infected 293T and 296 L929 cells are comparable with that infected with m8∆-pSFJ-JRCSFenv and even 297 more in m8∆-p7.5-JRCSFenv-infected RK13 cells, which is different from the case of 298 gp160/gp120 (Fig 1B) . Considering the better replication of m8∆-p7.5-JRCSFenv 299 (Fig 1C) , we may expect that repetitive antigenic stimulation, which favors CTL 300 induction, strengthens the immunogenicity of gp41 that is derived from m8Δ-p7.5-301
JRCSFenv to induce production of Env-specific IFN-γ + CD107a + CD8 + T cells. The 302 relative lower ratio of gp41to gp160/gp120 in m8∆-pSFJ-JRCSFenv-infected cells 303 than m8∆-p7.5-JRCSFenv cells indicates that the cleavage of gp160 to gp120 and 304 gp41 was less efficient due to overexpression of Env. 305
On the other hand, the efficient production of anti-Env-specific antibodies may 306 require higher expression of HIV-1 Env in primarily-infected cells. The 6-7 fold 307 higher level of the HIV-1 Env binding antibody titre observed in mice immunized 308 with m8∆-pSFJ-JRCSFenv is consistent with the higher levels of Env observed in 309 m8∆-pSFJ-JRCSFenv-infected cells. The Gp120/160 isolated from m8∆-pSFJ-310
JRCSFenv-infected cells migrated more quickly and showed a broader band in PAGE 311 gels than that from m8∆-p7.5-JRCSFenv-infected cells. This suggests the incomplete 312 glycosylation of gp120/160 due to an insufficiency of host glycosyltransferases. 313
Nevertheless, the impact on the ability of m8∆-pSFJ-JRCSFenv to elicit anti-Env 314 antibody response was minimal. Although m8∆-pSFJ-JRCSFenv induced greater 315 production of Env binding Abs than m8Δ-p7.5-JRCSFenv, it did not induce the 316 production of more potent anti-HIV-1 neutralizing Abs. At 8 weeks after rSeV-317
JRCSFenv boost, the average ID50 of serum from mice immunized with m8∆-pSFJ-318
JRCSFenv was higher than that of serum from mice immunized with m8∆-p7.5-319
JRCSFenv; however, the difference was not significant. This suggests that, in addition 320 to the amount of expressed Env, the properties of the antigen (for example, the 321 structure of the exposed epitopes) may also be important for the induction of 322 neutralizing antibody production. There was no difference in the avidity of the anti-323
Env antibodies between the two groups (Fig 3C) , implicating that the process of14 affinity maturation was similar. This suggests that affinity maturation of antibodies is 325 necessary, but not sufficient to induce the production of potent neutralizing antibodies. 326
Even so, higher levels of Env binding antibodies may enable the induction of other 327 types of antiviral immunity, such as antibody-dependent cellular cytotoxicity and 328 antibody-dependent cell-mediated virus inhibition. 329
We recently showed that priming mice with an m8∆ that expresses both CD40Lm and 330
Env induces the production of high-avidity anti-Env antibodies [2] . The above results 331 suggest that it might be important to incorporate an adjuvant, such as CD40Lm, 332 within the AIDS vaccine regimen to induce more potent humoral responses and 333 produce higher levels of neutralizing antibodies. 334
A successful AIDS vaccine should induce the production of long-lasting antibodies. 335
Both m8∆-pSFJ-JRCSFenv and m8∆-p7.5-JRCSFenv induced the production of long-336 lasting anti-Env antibodies when used in the rm8∆s prime/rSeV boost regimen. 337
Immunized mice maintained high levels of anti-Env antibodies for up to 28 weeks 338 (Fig 3D) . This supports our previous report showing that the rm8∆s prime/rSeV 339 regimen is a good platform for the development of an HIV-1 vaccine. 340
Safety is critical when evaluating vaccines in clinical trials. Both m8∆-pSFJ-341
JRCSFenv and m8∆-p7.5-JRCSFenv were less virulent in new-born mice than the 342 parental strain, LC16m8∆. LC16m8∆ was more virulent probably because it contains 343 an intact HA gene. The LD50 of m8Δ-p7.5-JRCSFenv was significantly lower than 344 that of m8ΔVNC110, although their growth potential was similar. This suggests that 345 the expression of HIV-1 Env in the mouse brain is harmful. This is supported by the 346 fact that that virulence of m8Δ-pSFJ-JRCSFenv is similar to that of m8ΔVNC110, 347 despite having a much lower capacity for replication. Nevertheless, our finding that 348 recombinant VVs expressing HIV-1 env are safer than LC16m8Δ suggests that they 349 may be promising candidates for clinical trials. 350
In conclusion, the results of the present study suggest that VV m8∆ vectors containing 
